Genta Inc. on Thursday announced that it filed aninvestigational new drug application (IND) with the FDA tobegin testing a new topical corticosteroid formulation fortreating eczema and atopic dermatitis.

The formulation, G-203, is a patented fluocinonide single-usewipe designed to localize the corticosteroid at the site ofapplication, the San Diego company said. Fluocinonide is thegeneric name for the leading corticosteroid used to treat mildinflammation, including eczema and atopic dermatitis, andGenta said its new formulation is designed to maintain thesteroid at the application site.

(c) 1997 American Health Consultants. All rights reserved.